As revealed in our previous work [33], c-MET high signature in combination with PTEN loss of function mutation also predicted poor prognosis of HCC patients and showed sensitivity to FASN inhibitors rather than tyrosine kinase inhibitors. Here, FASN is linked to hepatocellular carcinoma.